Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats
Synaptic dysfunction is hypothesised to play a key role in schizophrenia pathogenesis. Here, using [11C]UCB-J PET, the authors show for the first time in vivo that levels of the synaptic marker protein SV2A are reduced in schizophrenia and unaffected by antipsychotic treatment in a rat model.
Guardado en:
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d2e6a5e593d0405db0ad2d55f3b35447 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:d2e6a5e593d0405db0ad2d55f3b35447 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:d2e6a5e593d0405db0ad2d55f3b354472021-12-02T14:42:47ZSynaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats10.1038/s41467-019-14122-02041-1723https://doaj.org/article/d2e6a5e593d0405db0ad2d55f3b354472020-01-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-14122-0https://doaj.org/toc/2041-1723Synaptic dysfunction is hypothesised to play a key role in schizophrenia pathogenesis. Here, using [11C]UCB-J PET, the authors show for the first time in vivo that levels of the synaptic marker protein SV2A are reduced in schizophrenia and unaffected by antipsychotic treatment in a rat model.Ellis Chika OnwordiEls F. HalffThomas WhitehurstAyla MansurMarie-Caroline CotelLisa WellsHannah CreeneyDavid BonsallMaria RogdakiEkaterina ShatalinaTiago Reis MarquesEugenii A. RabinerRoger N. GunnSridhar NatesanAnthony C. VernonOliver D. HowesNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-11 (2020) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Science Q |
spellingShingle |
Science Q Ellis Chika Onwordi Els F. Halff Thomas Whitehurst Ayla Mansur Marie-Caroline Cotel Lisa Wells Hannah Creeney David Bonsall Maria Rogdaki Ekaterina Shatalina Tiago Reis Marques Eugenii A. Rabiner Roger N. Gunn Sridhar Natesan Anthony C. Vernon Oliver D. Howes Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats |
description |
Synaptic dysfunction is hypothesised to play a key role in schizophrenia pathogenesis. Here, using [11C]UCB-J PET, the authors show for the first time in vivo that levels of the synaptic marker protein SV2A are reduced in schizophrenia and unaffected by antipsychotic treatment in a rat model. |
format |
article |
author |
Ellis Chika Onwordi Els F. Halff Thomas Whitehurst Ayla Mansur Marie-Caroline Cotel Lisa Wells Hannah Creeney David Bonsall Maria Rogdaki Ekaterina Shatalina Tiago Reis Marques Eugenii A. Rabiner Roger N. Gunn Sridhar Natesan Anthony C. Vernon Oliver D. Howes |
author_facet |
Ellis Chika Onwordi Els F. Halff Thomas Whitehurst Ayla Mansur Marie-Caroline Cotel Lisa Wells Hannah Creeney David Bonsall Maria Rogdaki Ekaterina Shatalina Tiago Reis Marques Eugenii A. Rabiner Roger N. Gunn Sridhar Natesan Anthony C. Vernon Oliver D. Howes |
author_sort |
Ellis Chika Onwordi |
title |
Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats |
title_short |
Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats |
title_full |
Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats |
title_fullStr |
Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats |
title_full_unstemmed |
Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats |
title_sort |
synaptic density marker sv2a is reduced in schizophrenia patients and unaffected by antipsychotics in rats |
publisher |
Nature Portfolio |
publishDate |
2020 |
url |
https://doaj.org/article/d2e6a5e593d0405db0ad2d55f3b35447 |
work_keys_str_mv |
AT ellischikaonwordi synapticdensitymarkersv2aisreducedinschizophreniapatientsandunaffectedbyantipsychoticsinrats AT elsfhalff synapticdensitymarkersv2aisreducedinschizophreniapatientsandunaffectedbyantipsychoticsinrats AT thomaswhitehurst synapticdensitymarkersv2aisreducedinschizophreniapatientsandunaffectedbyantipsychoticsinrats AT aylamansur synapticdensitymarkersv2aisreducedinschizophreniapatientsandunaffectedbyantipsychoticsinrats AT mariecarolinecotel synapticdensitymarkersv2aisreducedinschizophreniapatientsandunaffectedbyantipsychoticsinrats AT lisawells synapticdensitymarkersv2aisreducedinschizophreniapatientsandunaffectedbyantipsychoticsinrats AT hannahcreeney synapticdensitymarkersv2aisreducedinschizophreniapatientsandunaffectedbyantipsychoticsinrats AT davidbonsall synapticdensitymarkersv2aisreducedinschizophreniapatientsandunaffectedbyantipsychoticsinrats AT mariarogdaki synapticdensitymarkersv2aisreducedinschizophreniapatientsandunaffectedbyantipsychoticsinrats AT ekaterinashatalina synapticdensitymarkersv2aisreducedinschizophreniapatientsandunaffectedbyantipsychoticsinrats AT tiagoreismarques synapticdensitymarkersv2aisreducedinschizophreniapatientsandunaffectedbyantipsychoticsinrats AT eugeniiarabiner synapticdensitymarkersv2aisreducedinschizophreniapatientsandunaffectedbyantipsychoticsinrats AT rogerngunn synapticdensitymarkersv2aisreducedinschizophreniapatientsandunaffectedbyantipsychoticsinrats AT sridharnatesan synapticdensitymarkersv2aisreducedinschizophreniapatientsandunaffectedbyantipsychoticsinrats AT anthonycvernon synapticdensitymarkersv2aisreducedinschizophreniapatientsandunaffectedbyantipsychoticsinrats AT oliverdhowes synapticdensitymarkersv2aisreducedinschizophreniapatientsandunaffectedbyantipsychoticsinrats |
_version_ |
1718389597393649664 |